MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.blre.2023.101128

Медицинская библиотека · Blood reviews · 2023

Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).

Stahl Maximilian, Bewersdorf Jan Philipp, Xie Zhuoer, Porta Matteo Giovanni Della, Komrokji Rami, Xu Mina L, Abdel-Wahab Omar, Taylor Justin, Steensma David P, Starczynowski Daniel T, Sekeres Mikkael A, Sanz Guillermo, Sallman David A, Roboz Gail J, Platzbecker Uwe, Patnaik Mrinal M, Padron Eric, Odenike Olatoyosi, Nimer Stephen D, Nazha Aziz, Majeti Ravi, Loghavi Sanam, Little Richard F, List Alan F, Kim Tae Kon, Hourigan Christopher S, Hasserjian Robert P, Halene Stephanie, Griffiths Elizabeth A, Gore Steven D, Greenberg Peter, Figueroa Maria E, Fenaux Pierre, Efficace Fabio, DeZern Amy E, Daver Naval G, Churpek Jane E, Carraway Hetty E, Buckstein Rena, Brunner Andrew M, Boultwood Jacqueline, Borate Uma, Bejar Rafael, Bennett John M, Wei Andrew H, Santini Valeria, Savona Michael R, Zeidan Amer M

СтатьяОбзорПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

The guidelines for classification, prognostication, and response assessment of myelodysplastic syndromes/neoplasms (MDS) have all recently been updated. In this report on behalf of the International Consortium for MDS (icMDS) we summarize these developments. We first critically examine the updated World Health Organization (WHO) classification and the International Consensus Classification (ICC) of MDS. We then compare traditional and molecularly based risk MDS risk assessment tools. Lastly, we discuss limitations of criteria in measuring therapeutic benefit and highlight how the International Working Group (IWG) 2018 and 2023 response criteria addressed these deficiencies and are endorsed by the icMDS. We also address the importance of patient centered care by discussing the value of quality-of-life assessment. We hope that the reader of this review will have a better understanding of how to classify MDS, predict clinical outcomes and evaluate therapeutic outcomes.

Для цитирования: Stahl Maximilian, Bewersdorf Jan Philipp, Xie Zhuoer, Porta Matteo Giovanni Della, Komrokji Rami, Xu Mina L, Abdel-Wahab Omar, Taylor Justin, Steensma David P, Starczynowski Daniel T, Sekeres Mikkael A, Sanz Guillermo, Sallman David A, Roboz Gail J, Platzbecker Uwe, Patnaik Mrinal M, Padron Eric, Odenike Olatoyosi, Nimer Stephen D, Nazha Aziz, Majeti Ravi, Loghavi Sanam, Little Richard F, List Alan F, Kim Tae Kon, Hourigan Christopher S, Hasserjian Robert P, Halene Stephanie, Griffiths Elizabeth A, Gore Steven D, Greenberg Peter, Figueroa Maria E, Fenaux Pierre, Efficace Fabio, DeZern Amy E, Daver Naval G, Churpek Jane E, Carraway Hetty E, Buckstein Rena, Brunner Andrew M, Boultwood Jacqueline, Borate Uma, Bejar Rafael, Bennett John M, Wei Andrew H, Santini Valeria, Savona Michael R, Zeidan Amer M. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).. Blood reviews. 2023. DOI: 10.1016/j.blre.2023.101128.

Предметные рубрики MeSH

HumansNeoplasmsMyelodysplastic SyndromesRisk AssessmentQuality of LifePrognosis
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.